Skip to content

Clinical controlled study for Huangqi Sini decoction in the treatment of severe chronic obstructive Pulmonary Disease

Clinical controlled study for Huangqi Sini decoction in the treatment of severe chronic obstructive Pulmonary Disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800017959
Enrollment
Unknown
Registered
2018-08-24
Start date
2018-09-01
Completion date
Unknown
Last updated
2018-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

2:inhaler + Huangqi Sini decoction
1:inhaler

Sponsors

Gansu Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Between 35 and 75 years of age; 2. According to the history of high-risk factors such as smoking, clinical symptoms, signs, chest radiographs and lung function tests, FEV1/FVC < 70% and FEV1 < 50% predictive values after inhalation of bronchodilator can be determined as incomplete reversible airflow limitation and classified as severe or very severe. A few patients have no symptoms such as cough, sputum, and only lung function show that FEV1/FVC < 70% and FEV1 < 50% have no evidence for other diseases also can be diagnosed as severe COPD; 3. TCM syndrome type standard: syndrome differentiation for spleen and kidney yang deficiency patients.

Exclusion criteria

Exclusion criteria: 1. Syndrome differentiation for yin deficiency of the body; 2. With a history of allergy to traditional Chinese medicine; 3.Severe patients requiring continuous tracheal intubation ventilator assisted breathing; severe pulmonary interstitial fibrosis, active pulmonary tuberculosis, lung cancer; 4. Severe extrapulmonary organ failure: liver and kidney failuresevere primary diseases such as nervous system, digestive system, urinary system,hematopoietic system, and psychosis; 5.One month before entering the group, the use of over-regulation of lung and kidney herbs or other immunomodulating drugs; 6. Family members refuse treatment.

Design outcomes

Primary

MeasureTime frame
Spirometry;blood and gas analysis;

Secondary

MeasureTime frame
SPO2;6 minite walking test;

Countries

China

Contacts

Public ContactLandi Wang

Gansu Provincial Hospital

878832034@qq.com+86 15002591569

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026